title: Early impact and performance characteristics of an established anal dysplasia screening program: program evaluation considerations.
abstract: BACKGROUND
  Screening for invasive anal cancer and its precursors is being increasingly advocated as a response to increasing incidence among HIV-infected persons. We implemented a comprehensive screening program in 2001 and report our early experience to inform monitoring and evaluation of such programs. Our research aims were: (1) to estimate incidence of and mortality from invasive anal cancer (IAC) before (1995-2000) and after (2001-2005) screening program implementation and (2) to examine potential screening program quality indicators.
  
  
  METHODS
  The study cohort included all patients under care for HIV infection at UCSD Owen Clinic between 1995-2005. Person-time incidence rates (IR) and case survival of IAC were estimated for the pre-screening (1995-2000) and post-screening (2001-2005) periods. High resolution anoscopy (HRA) operator accuracy was estimated by kappa agreement between cyto-histologic comparisons. Program quality indicators included: (1) screening coverage; (2) percent technically unsatisfactory cytology smears; (3) time between 1st abnormal cytology and 1st HRA; and (4) time between last clinic visit and last cytology.
  
  
  RESULTS
  28 cases of IAC and 13,411 person-years were observed between 1995-2005. IRs (95% CI) pre-screening and post-screening were 199 and 216 per 100,000 person-years, respectively. There was no routine treatment of high grade squamous intraepithelial lesions (HSIL) during the study period. The percent of patients with IAC requiring chemoradiation decreased from 90.9% to 70.6% (p=0.36). There was a significant improvement in cyto-histologic agreement at HRA with increasing operator experience (r=0.92, p=0.025). Screening coverage was 73% of the target population. Among 14 providers, the percent unsatisfactory cytology smears averaged 27% but varied from 0 - 62%. The median time from 1st abnormal cytology to 1st HRA was 258 days. The median interval between the last cytology and the last clinic visit was 207 days.
  
  
  CONCLUSIONS
  (1) The overall IR of IAC did not decline in the screening era and was higher than previous estimates for HIV cohorts; (2) stage shift to IAC of more favorable prognosis is a reasonable screening goal; (3) HRA accuracy varied by provider experience; (4) because of delay in access to HRA, digital rectal exam should be combined with cytology screening to detect palpable disease.
authors.affiliation: Department of Medicine, University of California, San Diego, 200 West Arbor Drive. San Diego, CA 92103-8681, USA. cmathews@ucsd.edu
authors.forename: Christopher
authors.initials: C
authors.lastname: Mathews
authors.forename: Joseph
authors.initials: J
authors.lastname: Caperna
authors.forename: Edward R
authors.initials: ER
authors.lastname: Cachay
authors.forename: Bard
authors.initials: B
authors.lastname: Cosman
references.citation: Acta Cytol. 2005 Jul-Aug;49(4):405-15
references.pmid: 16124170
references.citation: Fam Med. 1998 May;30(5):350-5
references.pmid: 9597533
references.citation: Prev Med. 2004 Aug;39(2):404-12
references.pmid: 15226053
references.citation: J Infect Dis. 2003 Jul 1;188(1):128-36
references.pmid: 12825181
references.citation: Oncologist. 2007 May;12(5):524-34
references.pmid: 17522240
references.citation: Sex Transm Infect. 2005 Oct;81(5):415-8
references.pmid: 16199742
references.citation: Obstet Gynecol. 1998 Oct;92(4 Pt 2):727-35
references.pmid: 9764690
references.citation: Fam Med. 2005 May;37(5):360-3
references.pmid: 15883903
references.citation: Clin Infect Dis. 2002 Nov 1;35(9):1127-34
references.pmid: 12384848
references.citation: Prev Med. 1977 Dec;6(4):487-99
references.pmid: 600908
references.citation: IARC Sci Publ. 1985;(66):45-63
references.pmid: 4093187
references.citation: Cytojournal. 2004 Oct 21;1(1):4
references.pmid: 15504231
references.citation: J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5
references.pmid: 15577418
references.citation: N Engl J Med. 2007 Oct 18;357(16):1579-88
references.pmid: 17942871
references.citation: Ann Intern Med. 2002 Sep 3;137(5 Pt 2):435-78
references.pmid: 12617574
references.citation: Int J Gynecol Pathol. 1993 Apr;12(2):186-92
references.pmid: 8463044
references.citation: Diagn Cytopathol. 2005 Sep;33(3):152-6
references.pmid: 16078257
references.citation: Cochrane Database Syst Rev. 2004;(3):CD004323
references.pmid: 15266529
references.citation: Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):226-32
references.pmid: 16054967
references.citation: Eur J Cancer. 1998 Sep;34(10):1598-601
references.pmid: 9893635
references.citation: Am J Epidemiol. 2007 May 15;165(10):1143-53
references.pmid: 17344204
references.citation: Br J Surg. 2005 Sep;92(9):1133-6
references.pmid: 16044425
references.citation: BMJ. 1998 Aug 1;317(7154):307-12
references.pmid: 9685274
references.citation: Top HIV Med. 2003 Mar-Apr;11(2):45-9
references.pmid: 12717041
references.citation: Dis Colon Rectum. 2006 Jan;49(1):36-40
references.pmid: 16283561
references.citation: Colorectal Dis. 2003 May;5(3):206-13
references.pmid: 12780879
references.citation: Cancer. 2004 Jul 15;101(2):281-8
references.pmid: 15241824
references.citation: N Engl J Med. 2007 Oct 18;357(16):1589-97
references.pmid: 17942872
references.citation: Dis Colon Rectum. 2006 Oct;49(10):1648-9; author reply 1649-50
references.pmid: 16972138
references.citation: Sex Health. 2004;1(3):137-40
references.pmid: 16335300
references.citation: Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31
references.pmid: 10219805
references.citation: IARC Sci Publ. 1986;(76):185-98
references.pmid: 3570404
references.citation: Int J Colorectal Dis. 2002 Jul;17(4):203-15
references.pmid: 12073068
references.citation: Sex Transm Dis. 2007 Mar;34(3):170-3
references.pmid: 16837830
references.citation: J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5
references.pmid: 16280701
references.citation: Obstet Gynecol. 2003 Jan;101(1):29-37
references.pmid: 12517642
references.citation: J Natl Cancer Inst. 1999 Feb 3;91(3):252-8
references.pmid: 10037103
references.citation: Sex Transm Dis. 2005 May;32(5):314-20
references.pmid: 15849533
references.citation: Crit Rev Oncol Hematol. 2006 Mar;57(3):215-24
references.pmid: 16371251
references.citation: Dis Colon Rectum. 1997 Aug;40(8):919-28
references.pmid: 9269808
references.citation: Cancer. 2004 Sep 1;101(5 Suppl):1131-45
references.pmid: 15316907
references.citation: Am J Obstet Gynecol. 2001 Aug;185(2):507-13
references.pmid: 11518918
references.citation: Ned Tijdschr Geneeskd. 2000 Dec 2;144(49):2345-8
references.pmid: 11129969
references.citation: Br Med J (Clin Res Ed). 1986 Sep 13;293(6548):659-64
references.pmid: 3092971
references.citation: Am J Pediatr Hematol Oncol. 1992 May;14(2):117-28
references.pmid: 1530116
references.citation: Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):619-26
references.pmid: 7827594
references.citation: Epidemiology. 2002 Nov;13(6):713-7
references.pmid: 12410014
references.citation: Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5
references.pmid: 15630846
references.citation: J Med Screen. 2005;12(1):12-9
references.pmid: 15825234
references.citation: Am J Public Health. 1978 Feb;68(2):125-34
references.pmid: 626255
references.citation: J Gen Intern Med. 1990 Sep-Oct;5(5 Suppl):S14-6
references.pmid: 2231057
references.citation: J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5
references.pmid: 15577408
references.citation: Surg Today. 2006;36(10):885-91
references.pmid: 16998682
references.citation: Am J Epidemiol. 1988 Dec;128(6):1185-97
references.pmid: 3057878
references.citation: Br J Surg. 2006 May;93(5):531-8
references.pmid: 16607677
references.citation: Am J Obstet Gynecol. 2006 Mar;194(3):704-10
references.pmid: 16522401
references.citation: Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim
references.pmid: 16396154
references.citation: Health Qual Life Outcomes. 2007 Jan 08;5:3
references.pmid: 17210071
references.citation: Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85
references.pmid: 15890590
references.citation: Clin Infect Dis. 2006 Jul 15;43(2):223-33
references.pmid: 16779751
references.citation: Med J Aust. 1999 Mar 15;170(6):255-8
references.pmid: 10212646
references.citation: JAMA. 1999 May 19;281(19):1822-9
references.pmid: 10340370
references.citation: Gynecol Oncol. 2003 Jul;90(1):137-44
references.pmid: 12821354
references.citation: Surg Oncol. 2005 Nov;14(3):121-32
references.pmid: 16165347
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9
references.pmid: 9525431